Key statistics
As of last trade Zenas Biopharma Inc (ZBIO:NSQ) traded at 26.67, -40.21% below its 52-week high of 44.60, set on Dec 24, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 25.61 |
|---|---|
| High | 27.25 |
| Low | 25.61 |
| Bid | 26.53 |
| Offer | 26.80 |
| Previous close | 26.11 |
| Average volume | 927.55k |
|---|---|
| Shares outstanding | 53.68m |
| Free float | 39.40m |
| P/E (TTM) | -- |
| Market cap | 1.40bn USD |
| EPS (TTM) | -12.67 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 15:52 GMT.
More ▼
- Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
- Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
- Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
- Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
- Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
More ▼
